BC Week In Review | Apr 30, 2012
Company News

Aptalis Pharma, Teva, Mylan, Par Pharmaceutical musculoskeletal news

The U.S. Court of Appeals for the Federal Circuit (CAFC) reversed and vacated a lower court's ruling last year that two patents from Aptalis and Teva's Cephalon Inc. subsidiary covering muscle relaxant Amrix cyclobenzaprine were...
BioCentury | May 30, 2011
Finance

Europe's Iceberg 2011: Unlocking hidden value

The European biotech industry is now about a generation old - long enough for investors and managements to benefit from the experiences of several business cycles. While it is easy to complain about the flaws in...
BC Week In Review | May 23, 2011
Company News

Anchen Pharmaceuticals Inc., Axcan, Cephalon, Teva, Impax, Mylan musculoskeletal news

The U.S. District Court for the District of Delaware issued a temporary restraining order enjoining Mylan from manufacturing, using, offering to sell or selling a generic version of muscle relaxant Amrix cyclobenzaprine pending an appeal...
BC Week In Review | Apr 18, 2011
Company News

Anchen Pharmaceuticals Inc., Axcan, Cephalon, Teva, Impax, Mylan musculoskeletal news

The U.S. District Court for the District of Delaware enjoined the defendants from launching generic versions of muscle relaxant Amrix cyclobenzaprine until the court issues its opinion on several patent infringement cases over the compound....
BioCentury | Apr 4, 2011
Finance

Eleventh Hour Push

A last minute surge led by large cap stocks enabled biotech indices to post a strong performance for the first quarter. Prior to that, biotech had been relatively flat or down for most of the...
BC Week In Review | Feb 21, 2011
Company News

Axcan, Eurand deal

Axcan Pharma Inc. , Mont-Saint-Hilaire, Quebec   Eurand N.V. (NASDAQ:EURX), Amsterdam, the Netherlands   Business: Gastrointestinal   Axcan completed its previously announced tender offer for partner Eurand, acquiring about 45.9 million shares (95.6%) for $12 per...
BC Week In Review | Feb 7, 2011
Company News

Axcan, Eurand deal

Axcan Pharma Inc. , Mont-Saint-Hilaire, Quebec   Eurand N.V. (NASDAQ:EURX), Amsterdam, the Netherlands   Business: Gastrointestinal   Axcan extended to 12:01 am EST on Feb. 11 from Feb. 3 the deadline for its tender offer to...
BC Week In Review | Jan 31, 2011
Company News

Axcan, Eurand deal

Axcan Pharma Inc. , Mont-Saint-Hilaire, Quebec   Eurand N.V. (NASDAQ:EURX), Amsterdam, the Netherlands   Business: Gastrointestinal   Axcan extended to 12:01 am EST on Feb. 3 the deadline for its tender offer to acquire partner Eurand...
BioCentury | Jan 24, 2011
Product Development

Really insufficient

Solpura liprotamase for exocrine pancreatic insufficiency could be the poster child for why it's a good idea to run head-to-head clinical trials. If those had been done early on, the product might now be on...
BC Week In Review | Jan 17, 2011
Company News

Eurand, Nycomed sales and marketing update

Eurand granted Nycomed exclusive commercialization rights to Zenpep pancrelipase in Russia, the Commonwealth of Independent States (CIS), Georgia and Mongolia. The porcine-derived pancreatic enzyme product (PEP) is marketed by Eurand in the U.S. to treat...
Items per page:
1 - 10 of 134
BC Week In Review | Apr 30, 2012
Company News

Aptalis Pharma, Teva, Mylan, Par Pharmaceutical musculoskeletal news

The U.S. Court of Appeals for the Federal Circuit (CAFC) reversed and vacated a lower court's ruling last year that two patents from Aptalis and Teva's Cephalon Inc. subsidiary covering muscle relaxant Amrix cyclobenzaprine were...
BioCentury | May 30, 2011
Finance

Europe's Iceberg 2011: Unlocking hidden value

The European biotech industry is now about a generation old - long enough for investors and managements to benefit from the experiences of several business cycles. While it is easy to complain about the flaws in...
BC Week In Review | May 23, 2011
Company News

Anchen Pharmaceuticals Inc., Axcan, Cephalon, Teva, Impax, Mylan musculoskeletal news

The U.S. District Court for the District of Delaware issued a temporary restraining order enjoining Mylan from manufacturing, using, offering to sell or selling a generic version of muscle relaxant Amrix cyclobenzaprine pending an appeal...
BC Week In Review | Apr 18, 2011
Company News

Anchen Pharmaceuticals Inc., Axcan, Cephalon, Teva, Impax, Mylan musculoskeletal news

The U.S. District Court for the District of Delaware enjoined the defendants from launching generic versions of muscle relaxant Amrix cyclobenzaprine until the court issues its opinion on several patent infringement cases over the compound....
BioCentury | Apr 4, 2011
Finance

Eleventh Hour Push

A last minute surge led by large cap stocks enabled biotech indices to post a strong performance for the first quarter. Prior to that, biotech had been relatively flat or down for most of the...
BC Week In Review | Feb 21, 2011
Company News

Axcan, Eurand deal

Axcan Pharma Inc. , Mont-Saint-Hilaire, Quebec   Eurand N.V. (NASDAQ:EURX), Amsterdam, the Netherlands   Business: Gastrointestinal   Axcan completed its previously announced tender offer for partner Eurand, acquiring about 45.9 million shares (95.6%) for $12 per...
BC Week In Review | Feb 7, 2011
Company News

Axcan, Eurand deal

Axcan Pharma Inc. , Mont-Saint-Hilaire, Quebec   Eurand N.V. (NASDAQ:EURX), Amsterdam, the Netherlands   Business: Gastrointestinal   Axcan extended to 12:01 am EST on Feb. 11 from Feb. 3 the deadline for its tender offer to...
BC Week In Review | Jan 31, 2011
Company News

Axcan, Eurand deal

Axcan Pharma Inc. , Mont-Saint-Hilaire, Quebec   Eurand N.V. (NASDAQ:EURX), Amsterdam, the Netherlands   Business: Gastrointestinal   Axcan extended to 12:01 am EST on Feb. 3 the deadline for its tender offer to acquire partner Eurand...
BioCentury | Jan 24, 2011
Product Development

Really insufficient

Solpura liprotamase for exocrine pancreatic insufficiency could be the poster child for why it's a good idea to run head-to-head clinical trials. If those had been done early on, the product might now be on...
BC Week In Review | Jan 17, 2011
Company News

Eurand, Nycomed sales and marketing update

Eurand granted Nycomed exclusive commercialization rights to Zenpep pancrelipase in Russia, the Commonwealth of Independent States (CIS), Georgia and Mongolia. The porcine-derived pancreatic enzyme product (PEP) is marketed by Eurand in the U.S. to treat...
Items per page:
1 - 10 of 134